Wednesday, January 21, 2026 Congratulations to Dr. Simron Singh who was named as Chair in Neuroendocrine Medical and Systemic Cancer Care & Research, jointly shared by Sunnybrook Health Sciences Centre and the University of Toronto’s Temerty Faculty of Medicine. As Chair he will support a combination of clinical trial innovation, precision biomarker discovery, and translational research integration at Sunnybrook. Dr Singh is the co-chair of the CCTG neuroendocrine disease oriented group (NDOG) and the Canadian chair of the CCTG NE1 NET RETREAT study of 177Lutetium-DOTATATE Retreatment vs. Everolimus or Sunitinib or Cabozantinib in Metastatic/unresectable Gastroenteropancreatic Tumours. This trial invovles a unique collaboration, a National Clinical Trials Network (NCTN) trial which was co-developed between CCTG with Dr Simron Singh and SWOG with Dr Aman Chauhan and a first from the NCI Gastroinstestinal Steering Committee that CCTG is leading.He is also the co-creator of the Commonwealth Neuroendocrine Tumor Research Collaborative linking international investigators and enabling impactful global studies and co-head of the U.S. National Cancer Institute’s Neuroendocrine Task Force for his second term, providing direct insight into North American clinical trial strategy, and president of the North American Neuroendocrine Tumor Society (NANETS) and the first Canadian to hold this role.
